Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
JHP Pharmaceuticals Acquired By Warburg Pincus

PARSIPPANY, N.J. and NEW YORK, Dec. 31, 2012 /PRNewswire/ -- JHP Pharmaceuticals, LLC ("JHP"), a specialty pharmaceutical company that acquires, develops, manufactures and sells sterile injectable products, today announced that it has been acquired by an affiliate of Warburg Pincus, a leading global private equity firm focused on growth investing, from JHP Holdings, LLC, an entity majority-owned by Morgan Stanley Principal Investments, for $195 million on a debt-free, cash-free basis.  JHP's current management team will continue to hold an interest in the company. Additional terms of the transaction were not disclosed.

Since its founding in 2007, JHP has developed into a leading specialty pharmaceutical company focused on the $30 billion U.S. sterile injectable drug market.  JHP's established market presence, high-quality sterile manufacturing facility, and experienced management team, coupled with growth capital and support from Warburg Pincus, will enable the company to pursue unique partnership and acquisition opportunities in both the branded and generic segments of the sterile injectable market.

"Over the past five years, JHP has established itself as a strong injectable pharmaceutical business manufacturing and marketing its own branded and generic products, developing a strong generic products pipeline, and supporting other pharmaceutical companies in the development and manufacturing of innovative products," said Stuart Hinchen, co-founder and CEO of JHP.  "In 2013, we will launch the first products from our strong pipeline of generic products.  We believe Warburg Pincus is an ideal partner for JHP's growth and expansion in the coming years.  Warburg Pincus has deep experience in healthcare and pharmaceuticals in particular and is well known for its proven ability to strengthen the platforms of its portfolio companies."

"With the support of Warburg Pincus, we will be able to embrace a more expansive strategy that will result in a considerably deeper and broader development pipeline for JHP," said Peter Jenkins, co-founder of JHP.

"We have been impressed with the financial performance and quality record of JHP over the last five years, and are very pleased to contribute to the further development of the company," said Elizabeth H. Weatherman, Managing Director and Head of the Healthcare Group, Warburg Pincus.  "The management team has done an excellent job building the company and we are delighted they are remaining with the business and co-investing.   JHP represents an attractive investment opportunity for us and we have reserved a sizeable amount of additional capital to fund growth opportunities that will transform the business well beyond what it is today."

Advisors

Morgan Stanley & Co. LLC acted as financial advisor to JHP Holdings, LLC, and Wachtell, Lipton, Rosen & Katz acted as legal advisor to the Special Committee of the Board of Directors of JHP Holdings, LLC.  Duff & Phelps LLC provided a fairness opinion to the Special Committee of the Board of Directors of JHP Holdings, LLC.  Willkie Farr & Gallagher LLP acted as legal advisor to Warburg Pincus LLC.

About JHP Pharmaceuticals, LLC

JHP, headquartered in New Jersey, is a fully integrated specialty pharmaceutical company that acquires, develops, manufactures and sells sterile injectable products.  JHP's sterile manufacturing facility, located in Rochester, Michigan, sits on over 80 acres of land and includes a 171,000 sq. ft. production building and warehouse.  JHP employs more than 370 staff in the USA in its manufacturing, product development, sales & marketing and corporate areas.  For more information, please visit www.jhppharma.com.

About Warburg Pincus

Warburg Pincus is a leading global private equity firm focused on growth investing. The firm has more than $30 billion in assets under management. Its active portfolio of more than 125 companies is highly diversified by stage, sector and geography. Warburg Pincus is an experienced partner to management teams seeking to build durable companies with sustainable value. Founded in 1966, Warburg Pincus has raised 13 private equity funds which have invested more than $40 billion in over 650 companies in more than 30 countries.

Since inception, the firm has invested over $8.1 billion in more than 140 healthcare companies, including investments in American Medical Systems, Bausch + Lomb, Coventry Health Care, Eurand (acquired by Axcan in 2011), Euromedic International (acquired by Merrill Lynch Global Private Equity and Ares Life Sciences in 2008), Harbin Pharmaceuticals, Lepu Medical Technology, RegionalCare Hospital Partners, ReSearch Pharmaceutical Services, Rural/Metro Corporation, Tornier and Zentiva (acquired by sanofi-aventis in 2009).

The firm is headquartered in New York with offices in Amsterdam, Beijing, Frankfurt, Hong Kong, London, Luxembourg, Mauritius, San Francisco, Sao Paulo and Shanghai. For more information, please visit www.warburgpincus.com.
Contact:

JHP
Stuart Hinchen
973.658.3555 or stuart.hinchen@jhppharma.com

Ernie Toth
973.658.3569 or ernie.toth@jhppharma.com

Warburg Pincus
Ed Trissel / Jeffrey Smith
(212) 878-9288 / (212) 878-9205

SOURCE Warburg Pincus

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest AJAXWorld RIA Stories
SYS-CON Events announced today Isomorphic Software, the global leader in high-end, web-based business applications, will exhibit at SYS-CON's DevOps Summit 2015 New York, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Isomorphic Software is ...
One of the biggest challenges when developing connected devices is identifying user value and delivering it through successful user experiences. In his session at Internet of @ThingsExpo, Mike Kuniavsky, Principal Scientist, Innovation Services at PARC, described an IoT-specific...
The Internet of Things will greatly expand the opportunities for data collection and new business models driven off of that data. In her session at @ThingsExpo, Esmeralda Swartz, CMO of MetraTech, discussed how for this to be effective you not only need to have infrastructure and...
SYS-CON Events announced today that AgilePoint, the leading provider of Microsoft-centric Business Process Management software, will exhibit at SYS-CON's 2nd International @ThingsExpo which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara...
One of the biggest challenges when developing connected devices is identifying user value and delivering it through successful user experiences. In his session at Internet of @ThingsExpo, Mike Kuniavsky, Principal Scientist, Innovation Services at PARC, will describe an IoT-spe...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021


SYS-CON Featured Whitepapers
ADS BY GOOGLE